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Novel multiparameter correlates
of Coxiella burnetii infection
and vaccination identified
by longitudinal deep immune
profiling
P. M. Reeves1*, S. Raju Paul1, L. Baeten2, S. E. Korek1, Y. Yi1, J. Hess1, D. Sobell1,
A. Scholzen3, A. Garritsen3, A. S. De Groot4,5, L. Moise4,6, T. Brauns1, R. Bowen2,
A. E. Sluder1 & M. C. Poznansky1*
Q-fever is a flu-like illness caused by Coxiella burnetii (Cb), a highly infectious intracellular bacterium.
There is an unmet need for a safe and effective vaccine for Q-fever. Correlates of immune protection
to Cb infection are limited. We proposed that analysis by longitudinal high dimensional immune (HDI)
profiling using mass cytometry combined with other measures of vaccination and protection could be
used to identify novel correlates of effective vaccination and control of Cb infection. Using a vaccinechallenge model in HLA-DR transgenic mice, we demonstrated significant alterations in circulating
T-cell and innate immune populations that distinguished vaccinated from naïve mice within 10 days,
and persisted until at least 35 days post-vaccination. Following challenge, vaccinated mice exhibited
reduced bacterial burden and splenomegaly, along with distinct effector T-cell and monocyte profiles.
Correlation of HDI data to serological and pathological measurements was performed. Our data
indicate a Th1-biased response to Cb, consistent with previous reports, and identify Ly6C, CD73, and
T-bet expression in T-cell, NK-cell, and monocytic populations as distinguishing features between
vaccinated and naïve mice. This study refines the understanding of the integrated immune response to
Cb vaccine and challenge, which can inform the assessment of candidate vaccines for Cb.
Development of a safe, non-reactogenic and effective vaccine for Q-fever, a zoonotic disease found worldwide
caused by the obligate intracellular bacteria Coxiella burnetii (Cb), represents a current unmet need. Approximately 40% of Cb-infected individuals experience flu-like symptoms, while a subset develop pneumonia, endocarditis and/or hepatitis1–4. Cb can persist in the environment for long periods and inhalation of < 20 bacteria
can cause infection, raising public health concerns5–9. The current Q-fever vaccine for humans, Q-VAX, utilizes
inactivated whole-cell virulent Cb (phase I Henzerling strain) to elicit protective immunity against Cb10–12.
Q-VAX requires pre-screening to avoid reactogenicity in previously Cb-exposed individuals and is not considered
suitable for mass vaccination2,8,10,13–16. Subunit vaccines containing Cb epitopes to elicit protective T-cell responses
are a proposed strategy to bypass concerns related to LPS-induced reactogenicity17–20, while pre-clinical evaluation of candidate vaccines bearing computationally identified human-specific epitopes can be accomplished
in mice expressing human MHC a lleles21–23. The objective of this study was to generate immune profiling data
using mass cytometry, along with serological and pathological assessments, to identify novel correlates of effective vaccination and control of Cb infection that could ultimately inform the development of a safe and effective
vaccine for Q-fever.
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Figure 1.  Clinical outcomes of Coxevac vaccination and Cb challenge in tgHLA-DR3 mice. (A) Treatment
groups and numbers of mice for the tgHLA-DR3 study (B) Experimental schedule. Mice were injected
subcutaneously with saline or 10 µg Coxevac on day 0. After 42 days mice were challenged intranasally with live
Cb. Whole blood was collected for CyTOF analysis on Day 10, 35, 44 and 51. Sera were collected for serology on
Day 10, 24 and 35. (C) Antibody production against Cb was evaluated at Day 10, 24, and 35 post-vaccination by
ELISA (D) Spleen-to-body-weight ratio and (E) spleen bacterial burden (genome equivalents (GE) determined
by qPCR) were assessed for each of the experimental groups. Significant differences between experimental
groups in panels (C–E) were assessed by one-way ANOVA with the Tukey post-hoc multiple comparison
correction (****p = 0.0001, ***p < 0.0003, *p < 0.01). (F) Histopathological scores from lung, liver, spleen, and
heart. Kruskal–Wallis test was used to compare between groups (###p = 0.0003, ##p = 0.005).

Cb-infected individuals may retain epitope specific T-cell responses and anti-Cb antibodies for > 8 years,
though up to 20% become seronegative 4–6 years following infection24,25. Immunologic studies in mice demonstrate that MHC-II dependent responses are required for effective vaccination and T-cells predominantly act to
limit disease severity and burden, while B and NK cell responses contribute to c learance26–29. To further investigate the immune response to Cb, we sought to quantify the broader immune response to Cb in a vaccine–challenge model in mice. We conducted a longitudinal assessment of cellular and humoral immune responses to
vaccination in transgenic mice expressing the human MHC-II allele HLA-DR3 on a BL/6 background (tgHLADR3)30. Vaccination with Coxevac, a veterinary vaccine containing inactivated whole-cell virulent Cb, was followed by challenge with the same strain of Cb (phase-I Nine Mile strain)31. Mass cytometry (CyTOF) was used to
provide a comprehensive description of all major immune populations following vaccination and infection, and
multivariate statistical methods were used to evaluate the correlation of cell populations to antibody generation,
histopathology, and bacterial load. We identified novel correlates of Cb vaccination and infection characterized
by expression of Ly6C, CD73, and T-bet, among other key markers across distinct T-cell, B-cell, and innate
populations, and observed that key features of this response are detected in vaccinated mice. Our results reveal
the dynamic and broad immune response to Cb to support the development of subunit-based vaccines for Cb
and inform future investigations into immune pathogenesis of this and other intracellular pathogens.

Results

Determination of the vaccine dose that confers protection against Cb infection. BL/6 mice,
the tgHLA-DR3 background strain, were injected with increasing doses of Coxevac and intranasally (i.n.) challenged with Cb 42 days post-vaccination (Supplementary Fig. 1A)26. Ten days after challenge, mice were sacrificed to quantify splenic bacterial burden and splenomegaly, and to conduct histopathological scoring of heart,
lung, liver, and spleen (Supplementary Fig. 1). Increasing doses of Coxevac progressively reduced measures of
infection. Vaccination with 2 μg was sufficient to reduce splenomegaly, as measured by spleen-to-body-weight
ratio (%BW) and histopathological scoring, though not splenic burden (Supplementary Fig. 1B–D). Vaccination
with 10 μg effectively reduced all measures of infection and was used for subsequent experiments.
Longitudinal immunological assessment of Cb vaccination and challenge. We assessed the lon-

gitudinal profile of cellular immune responses to vaccination and challenge in tgHLA-DR3 mice in two independent replicate studies (Fig. 1A). Each study included 16 mice divided into naïve and vaccinated groups (n = 8
per group per study) that were sub-divided into challenge and uninfected groups (n = 4 per group per study,
Fig. 1A). One mouse assigned to the naïve-challenge group died on day 35, prior to challenge. On day 42 postvaccination, a subset of naïve and vaccinated mice was challenged i.n. with Cb. Blood was collected on days 10,
24, and 35 post-vaccination and days 2 and 10 post-infection (days 44 and 51 post-vaccination) (Fig. 1B). For
each cytometry timepoint, surface antigens were antibody-labelled following collection, and samples fixed to
inactivate viable Cb (Supplementary Table 1). Following confirmation of inactivation and release from biocontainment, intracellular epitopes were labeled, and samples analyzed by mass cytometry.
Pre-challenge antibody titers and quantitative measures of infection were also determined. Cb-specific antibodies increased from Days 10 to 35 post-vaccination (Fig. 1C). Following sacrifice on Day 10 post-challenge,
measures of bacterial burden, splenomegaly, and histopathology were determined. Challenge with Cb significantly increased splenomegaly (%BW) and bacterial burden in naïve mice as compared to unchallenged mice
(either naïve or vaccinated). In vaccinated mice, challenge did not significantly increase splenic measures of Cb
burden or %BW, as compared to unchallenged mice (Fig. 1D–E). Vaccination similarly reduced histology scores
for spleen, heart and lung. However, both vaccination and challenge independently resulted in elevated liver
histopathology (Fig. 1F). For vaccinated challenged mice, all but one exhibited moderate hepatic histopathology
(score = 1). One vaccinated challenged mouse had elevated spleen %BW, heart and spleen histopathology, though
no bacterial burden. Among the three vaccinated challenged mice with detectable bacterial burden, only one
was found to have both lung and spleen histopathology. Thus, vaccination with inactivated whole-cell Cb elicited
protective immunity sufficient to reduce bacterial burden and pathological measures overall, with evidence of
vaccine enhancement of splenic clearance by 10 days post-challenge in a subset of mice.

Identification of immune cell populations consistent between replicate experiments. The
high-parameter nature of mass cytometry data can provide multi-marker definitions of immune populations for
a detailed description of immune responses. Computational tools can simultaneously assess the abundance of
markers on individual cells to identify clusters of highly similar cells. We used a barcoding strategy to antibody
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label and acquire all samples from each timepoint as one cohesive unit. However, technical variations between
timepoints and between replicate experiments resulted in batch effects that precluded simultaneous identification of populations from all timepoints and replicates by clustering analysis.
We developed an approach to combine data from the two replicate experiments and thereby improve statistical
power for comparisons among treatment groups (Supplementary Fig. 2). Briefly, each timepoint from individual
replicate experiments was analyzed independently and cell clusters conserved between replicate timepoints were
identified (e.g. Day 10 experiment 1 and Day 10 experiment 2). First, cell profiling data from each timepoint
was analyzed individually to identify cell clusters computationally using X-shift32. Next, the resulting clusters
from replicate timepoints were matched on the basis of their phenotypic profiles and candidate pairs refined
according to abundance and overall distribution between treatment groups. For the resulting “matched clusters”
representing clusters conserved between two replicate timepoints, the data were combined to improve statistical
power of comparisons among treatment groups (see “Methods”).

Temporal changes in abundance of phenotypic immune cell classes. Matched clusters from all
timepoints were organized hierarchically to identify phenotypically similar clusters from across the experiment
for T-cell, B-cell, and innate populations (Fig. 2). The x-axis dendrogram indicates the influence of each marker
in defining cell classes. The antibody panel, which recognized a broad range of immune populations, provided
subsets of markers that dominate the heatmap for each of the three major populations. Through hierarchical
clustering, we identified “phenotypic classes” of cells which contain matched clusters bearing similar, though
not identical, marker profiles. Some classes contain clusters from multiple days or multiple clusters from a single
day. Phenotypic classes containing a single matched cluster were included, as they represented features observed
in two independent experiments. The analysis of T-cells resulted in 77 matched clusters in 19 phenotypic classes
(Fig. 2A). For B-cells, 92 matched clusters separated into 20 phenotypic classes (Fig. 2B). Within innate immune
populations, 60 matched clusters segregated into 14 phenotypic classes (Fig. 2C).
The capacity of each phenotypic class to predict classification of an individual mouse as naïve or vaccinated
was determined for pre-challenge timepoints using an elastic net (EN) logistic regression analysis (Fig. 3A,B)33.
EN analysis was conducted on post-challenge data to identify those classes that distinguish vaccinated challenged
and naïve challenged mice (Fig. 3C,D). To evaluate the temporal distribution of key classes, the frequency of
each phenotypic class through the time course was determined (Fig. 3E, Supplementary Fig. 4A–C). Following
vaccination, on Day 10 T-cell and innate immune classes distinguish naïve and vaccinated groups, with activated
T-cells linked to vaccinated mice. After 35 days, predictive B-cell classes appear, with Day 10 T-cell and innate cell
trends continuing. Challenge strongly polarized the predictive immune populations within 2 days post-challenge.
By Day 51, the most predictive clusters were activated CD4+ T-cells and monocyte/macrophages found in naïve
challenged mice. Detailed observations related to phenotypic families, as well as subsequent evaluation of individual clusters and correlation to experimental outcomes, are summarized in Table 1 and described further in
the Supplementary Material.
Correlation of cell clusters to measures of vaccination and infection. Grouping cell clusters into
phenotypic classes provides information on the distribution of cell populations through time and enables detection of phenotypic cell classes with predictive value. However, this approach does not assess the relationship of
individual populations to either experimental group or to measures of vaccination and infection. To determine
the link of individual populations to measured physiological data and treatment group, we conducted correlation and EN logistic regression analyses.
First, we determined the correlation of each matched cluster to antibody titer, splenic %BW, bacterial burden,
and histopathological scoring. Hierarchically organizing clusters on the basis of correlation values, independent
of timepoint or cellular marker profiles, delineated seven modules which were visualized using a t-SNE plot34
(Fig. 4A, Supplementary Fig. 5, Supplementary Table 2). The spatial distribution of clusters within the t-SNE is a
function of the similarity between cell clusters with respect to their correlations to measures of vaccination and
infection (Fig. 4B–I). The subset of clusters in Module 1 (Supplementary Table 3) consistently correlated with
elevated antibody titers (Fig. 4B,C; Day 24 titer not shown).
For each module, the median correlation of constituent clusters to antibody titer and measures of infection
was determined (Fig. 4J, Supplementary Table 3). Module 1 had the strongest association with antibody titer
and a negative correlation to all measures of infection. Modules 2 and 3 also correlated to increased antibody
titer, though with elevated correlation to splenic measures, Module 2 also showed an increased correlation to
liver histopathology, as compared with 1 & 3. Module 4 followed by Module 5 was the most linked to elevated
histopathological scores and negatively correlated to antibody titer; their adjacent positioning on the t-SNE is
consistent with their similar correlation properties. Overall, Modules 1, 4, and 5 had the strongest correlations
to vaccination-induced antibody production or measures of infection. The module assignments for key populations are noted in Table 1.
Predictive cells clusters to distinguish vaccinated from naïve mice. We next identified individual clusters and combinations of clusters that best differentiated, at each timepoint, between either vaccinated
and naïve mice or between challenged naïve and vaccinated mice at each timepoint. Individual clusters were
assessed as predictors of group assignment by EN logistic regression. The predictive clusters for each timepoint
are graphed to show their relative rank, as well as position on the correlation module t-SNE map (Fig. 5A–D);
individual predictive clusters are described further in the Supplementary Material. On Day 10, activated T-cell
and B-cell responses distinguish vaccinated mice, while naïve mice exhibited resting T-cell and mature innate
cell populations. By Day 35 a greater number of predictive populations were identified, with B-cell and innate
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Figure 2.  Identification of phenotypic classes of immune cell populations. Matched cell clusters from all timepoints,
determined as described in the text, were organized hierarchically (Y axes) based on relative marker expression levels (X axes
and heatmap color coding), using the Ward.D2 minimum variance method. Similar clusters were grouped into phenotypic
classes (delineated by white boundaries in heat maps); the number of classes were selected from unsupervised analysis using
NbClust and segmentation determined using dendrogram tree height. Hierarchical maps are shown for T cell (A), B Cell (B),
and innate immune populations (C).
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◂Figure 3.  Distribution of phenotypic classes across vaccination and challenge. For each timepoint, an EN

regression analysis was used to determine the probability of assignment to either experimental group, using the
median frequency of each phenotypic class per mouse on that day. The graphs identify cell classes with highest
predictive value for distinguishing vaccinated vs naïve mice pre-challenge (A,B) or vaccinated challenged
v naïve challenged mice (C,D) based on the magnitude of their logit coefficient, which is a measure of the
influence of change in the abundance of the cluster between experimental groups on the predictive value of the
cluster. Phenotypic class names are as assigned in Fig. 2. In panel E, plots indicate the median frequency and
standard deviation of a phenotypic class per experimental group across timepoints for selected classes that have
high predictive value. The dotted vertical line indicates intranasal challenge with Cb. For phenotypic classes with
multiple clusters at a given timepoint, all clusters are plotted individually. Plots of all classes are shown in Supp
Fig. 4A–C are provided in supplementary data.
populations most clearly distinguishing vaccinated mice, while mature monocyte and mature NK populations
characterized naïve mice. Following challenge, the number of predictive clusters decreased, with T-cell and
innate cell populations most prominently distinguishing challenged naïve and vaccinated groups.
To investigate the immune response in a more integrated manner, combinations of clusters that most clearly
distinguished vaccinated from naïve mice following either vaccination or challenge with Cb were determined.
The predictive capacity for every possible combination of up to 10 clusters for each timepoint was determined
using four computational selection methods (Supplementary Fig. 3). The optimal combination of clusters for
each timepoint was selected based on the consensus rank among the four measures, with strong agreement across
methods regarding accuracy and sensitivity (Table 2). Notably, for each day, the selected combination of clusters
was ranked highest by the neural net (NN) method at all timepoints, other than Day 51, when a requirement that
one or more clusters linked to vaccinated mice were included meant the combination ranked second by NN was
chosen, wherein innate cluster 4 was exchanged for innate cluster 5 (Supplementary Table 3). Consistent with
the individual cluster EN analysis, post-vaccination timepoints required more clusters to achieve maximum performance as compared to timepoints post-challenge: six clusters representing all major immune cell populations
were required 10 days after vaccination to best distinguish vaccinated and naïve mice. By Day 35 post-vaccination,
the combination of a single B-cell population and four innate immune populations, without T-cell populations,
was sufficient to discriminate between vaccinated and naïve mice. Following challenge, vaccinated mice could
be distinguished from naïve mice with four populations at two days post-challenge, and with two populations on
Day 10 after challenge. At both post-challenge timepoints, the indicated T-cell and innate populations (Table 2)
were sufficient to distinguish these groups, without requiring consideration of B-cell populations.
Together, these alterations in distribution of phenotypic classes and their constituent clusters provide
immunological signatures that distinguish treatment groups (Table 1). Vaccination increased the abundance
of CD8+ Ly6C+ CD73+ T-cells as well as CD4 + Ly6C+ T-cells by Day 10 post-vaccination. By Day 35 postvaccination these CD4+ cells were not apparent, while CD8+ cells were also expressing CD44+, suggesting
transition to a central memory phenotype. Both CD4+ and CD8+ T-cell populations expressing CD62L and
Ly6C were substantially increased 10 days post-challenge. Post-challenge, these increases were more prominent
in naïve mice, indicating an overall greater response from activated naïve T-cells.
These observations indicate that Ly6C+ cells in both naïve and memory peripheral T-cell populations are
increased following exposure to Cb, either through vaccination or intranasal challenge. Notably, the majority of
differences between treatment groups observed in innate cell populations were higher frequencies of circulating
monocyte, macrophage, and NK cell populations in naïve mice compared to vaccinated mice, following either
vaccination or challenge. In particular, T-bet+ NK populations, likely representing mature cells, were reduced
following vaccination, suggesting their mobilization to sites of inoculation. Overall, the number, distribution,
and respective phenotypes of clusters that best distinguish groups of mice at each timepoint (Table 2) identify
hallmarks of the immunological processes induced by vaccination and the differential response to challenge in
naïve and vaccinated mice.
We sought to determine if there were immunologic differences between the vaccinated mice that had no
detectable bacterial burden by Day 10 post-challenge and the three vaccinated mice that retained detectable Cb
(Fig. 1E). For each timepoint, combinations of up to three clusters were ranked by linear discriminant analysis
(LDA) for ability to distinguish between naïve challenged mice and the Cb-negative vaccinated challenged
mice. Next, to identify cell populations that distinguish Cb-positive vaccinated mice, the distributions of cluster
combinations were compared between the three challenge groups: naïve, Cb-negative, and Cb-positive. On Day
10 post-vaccination three T-cell clusters distinguished challenged naïve and vaccinated mice and also showed
a distribution in the three Cb-positive mice that trended towards naïve challenged mice (Fig. 6A). These three
clusters correspond to naïve Ly6C+ CD4+ and CD8+ populations increased in vaccinated mice and a naïve
Ly6C- CD8+ population enriched in naïve mice. Comparison of the three groups of mice on Day 35 identified a
combination of mature NK cells and a monocyte population associated with naïve mice and an activated memory
B-cell population in vaccinated mice (Fig. 6B). At two days post-challenge, a combination of CD4+ Ly6C+ Tbet+
T-cells and CD68+ mononuclear cells, both expressing TGFβ in vaccinated mice, along with a macrophage
population in naïve challenged mice, was selected by the analysis (Fig. 6C). At Day 10 post-challenge distinctions between the three groups were less robust. Nonetheless, a combination of central memory CD8+, effector
memory CD4+ T-cells, and a mature NK population all enriched in vaccinated mice was identified (Fig. 6D).
Despite the small group size, these data suggest signatures associated with vaccine efficacy that can be further
investigated in studies that include larger groups of mice or for evaluation of candidate Cb vaccines.

Scientific Reports |

(2020) 10:13311 |

https://doi.org/10.1038/s41598-020-69327-x

7
Vol.:(0123456789)

www.nature.com/scientificreports/

Phenotypic class (Fig. 2)
ID

EN Timepoint (Fig. 3)

EN
Clusters
(Fig. 5)

Correlation Module
(Fig. 4)
3
5
4

CD4 CD62L Ly6C

Key Markers Expressed

T2

D10 Vaccinated
D51 Naïve Challenged

T D10 Cluster 6
T D44 Cluster 13
T D51 Cluster 23

T3

D44 Vaccinated Challenged

T D44 Cluster 19

1

CD4 CD44
Ly6C T-bet TGFb

T4

D35 Vaccinated

T D10 Cluster 5
T D35 Cluster 2

3
6

CD4 CD62L CD44
Ly6C

T9

D10 Vaccinated

T D10 Cluster 3
T D35 Cluster 15
T D35 Cluster 3

5
7
5

CD4 CD44 CD62L

T13

D10 Vaccinated
D35 Vaccinated

T D10 Cluster 4
T D35 Cluster 10

1
1

CD8 CD62L CD44
Ly6C CD73

T16

D10 Naïve
D35 Vaccinated

T D10 Cluster 1
T D35 Cluster 6

4
6

CD8 CD62L CD44
CD73

T17

D10 Vaccinated

T D10 Cluster 8
T D35 Cluster 11

1
7

CD8 CD62L
Ly6C CD73

B2

D51 Naïve challenged

B D35 Cluster 3
B D51 Cluster 13

3
3

CD19 CD45R CD44
HLA-DR Ly6C

B4

D35 Vaccinated

B D35 Cluster 20

1

CD19 CD45R CD44
C62L HLA-DR CD115

B6

D35 Vaccinated

B D35 Cluster 10
B D35 Cluster 12

3
6

CD19 CD45R CD44
C62L HLA-DR

B18

D35 Naïve
D44 Naïve challenged

B D35 Cluster 15

4

CD19 CD45R CD44
Ly6C

I2

D10 Naïve

I D10 Cluster 11

5

CD11b CD44 F4/80 CD206 Ly6C Ly6G

I4

D51 Naïve Challenged

I D51 Cluster 13

4

CD11b CD44 CD68 F4/80 CD206 Ly6C HLA-DR

I5

D51 Naïve Challenged

I D35 Cluster 12
I D51 Cluster 4

6
4

CD11b CD11c
CD206 CD44 HLA-DR

I6

D35 Naïve

I D35 Cluster 5
I D35 Cluster 9
I D51 Cluster 5

4
7
1

CD11b CD11c
CD206 CD44

I8

D35 Vaccinated

I D35 Cluster 17

2

CD11c CD44 CD68
CD206 Ly6C

I9

D10 Naïve
D35 Naïve
D44 Naïve Challenged

I D10 Cluster 10
I D35 Cluster 19
I D44 Cluster 6
I D44 Cluster 8

4
4
5
7

CD44 CD73
CD206 Ly6C

I11

D10 Vaccinated
D35 Vaccinated

I D10 Cluster 1
I D35 Cluster 13

3
3

CD11b CD44
CD206 CD16

I12

D10 Naïve
D35 Naïve

I D10 Cluster 5
I D35 Cluster 2

5
5

CD335 CD44 CD11b CD206
T-bet

I14

D35 Naïve

I D35 Cluster 6
I D35 Cluster 10
I D35 Cluster 11

5
4
5

CD335 CD44 CD11b CD206
T-bet CD11c

Table 1.  Summary of cell populations associated with vaccination status. The table provides the information
on cell phenotypic classes and clusters identified through statistical analyses as associated with either naïve or
vaccinated mice pre- and post -challenge. For phenotypic classes selected by elastic net regression (EN), the
class identity (ID, Fig. 2) and timepoint(s) are noted (Fig. 3). Within each phenotypic class, those matched
clusters also identified by EN are noted, along with the correlation modules for each cluster (Supp Fig. 5).

Manual validation of marker expression in major immune cell populations. To confirm key fea-

tures identified by the statistical analysis of computationally-defined cell populations, all major immune populations were manually gated (Supp Fig. 3B), and the frequency of cells expressing Ly6C, T-bet, or CD73 was
determined. In this analysis, we observed increased expression of each of these individual markers following
vaccination and challenge (Fig. 7), consistent with the changes in cellular phenotypes identified computationally (Table 1). Significantly increased expression of T-bet was seen 10 days post-vaccination in CD4+ T-cells
and B-cells, and to a lesser, yet statistically significant, extent in CD8+ T-cells and dendritic cells. On Day 35
post-vaccination, the expression of T-bet had returned to near baseline levels in these cell populations. Ten days
post-challenge, naïve mice exhibit higher levels of T-bet in CD4+ T-cells, dendritic cells, and to a lesser extent in
inflammatory monocytes ( Ly6Chigh monocytes) as compared to vaccinated mice. The most pronounced increases
in Ly6C expression were observed 10 days following vaccination in CD8+ and CD4+ T-cells. B-cells and NK
cells also exhibited smaller, yet significant, post-vaccination increases in Ly6C expression at this timepoint. Two
days after challenge, CD4+ T-cells and B-cells from naïve challenged mice exhibited a greater increase in Ly6C
as compared to vaccinated challenged animals. CD73 expression increased in NK cells and to a lesser extent in
granulocytes 10 days post-vaccination, and with statistical significance in CD8+ T-cells 35 days post vaccination.
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Thus, manual gating analysis confirms the key features and markers identified based on computational clustering of immune populations.
A Circos plot was generated to visually summarize key data from all aspects of the experiment, while retaining information for individual mice (Fig. 8)35. The distinct profiles of naïve and vaccinated groups are readily
distinguished, as is the impact of challenge to further separate treatment groups. Features of naïve challenged
mice are particularly evident at Day 51, as are features of vaccinated challenged mice, such as the abundance of
mature NK cells that are shared with the unchallenged naïve and vaccine groups. Other features of vaccination
persist from 10 days post-vaccination until 2 days post-challenge, demonstrating the long-lasting impact of vaccination, even in the face of challenge with Cb. Pre-challenge naïve and vaccinated mice are largely distinguished
by differential abundance monocyte/macrophage populations, mature NK cells, and activated Th1 CD4 and CD8
T-cell populations. Following challenge, vaccinated and naïve mice exhibit distinct distributions of activated
naïve CD4 T-cells, Th1 polarized.
CD4 effector memory T-cells, and activated central memory CD8 cells, as well as subsets of monocytes and
activated macrophages. Interestingly, the Circos plot also illustrates a naïve challenged mouse (#5) with reduced
bacterial burden and splenomegaly with an immune profile similar to vaccinated challenged mice on Day 51.

Discussion

We report a longitudinal study of Cb vaccination and challenge in a transgenic humanized murine model and
describe for the first time the dynamics of all major immune cell populations in the response to Cb. Detailed
profiling of circulating immune cells by mass cytometry, together with discrete measures of vaccination and
infection with Cb, were used to identify novel hallmarks of the immune response to Cb. We developed an analysis workflow to meet the challenge of batch effects and interrogate data from two replicate studies. Subsequent
statistical analysis delineated immune populations, both individually and in combination, that distinguish naïve
from vaccinated mice through the course of the study. Further analysis determined the correlation of immune
populations to measures of vaccination and challenge. Together, these data reinforce the interconnected dynamics of the immune system, highlight cellular populations and markers that are important drivers of the immune
response to Cb, and will inform evaluation of future candidate vaccines.
Mass cytometry enabled detailed analysis of T-cell, B-cell, and innate (NK cell, granulocyte, and monocyte/
macrophage) populations in small blood volumes (< 200 μL) from mice under BSL3 containment, and metalconjugated antibodies were amenable to the extensive fixation necessary to inactivate Cb. Technical considerations of working with small blood volumes under BSL3 containment required that samples were processed and
antibody-labeled upon collection, rather than banked for simultaneous analysis of all study samples. Consequently, batch effects prevented simultaneous computational analysis of data across timepoints and replicate
experiments, thereby limiting statistical power. Several batch correction algorithms have been described for
CyTOF data; however, these tools were not sufficient to enable simultaneous clustering-based analysis of the data
from this study, or they require additional controls not included in our s tudy36–38. To analyze the multiple timepoints from two independent replicate experiments, we developed a novel workflow that leverages established
clustering and statistical analysis methods32,33,39,40. The strategy computationally defined cell clusters from each
timepoint separately for each replicate experiment and then matched clusters between replicate experiments
by phenotype. The resulting matched clusters retain source identity from each mouse as well as information for
each individual cell. The matched clusters from all timepoints were organized hierarchically, on the basis of their
expression profiles, to identify phenotypic classes and provide longitudinal context. Subsequent statistical analysis
enabled identification of populations associated with vaccination status as well as correlation to serological data
and measures of infection.
Our results suggest a potential role for Ly6C+ naïve T-cells soon after initial exposure to Cb, through either
vaccination or challenge. We observed multiple post-exposure CD4 and CD8 T-cell populations distinguished
by increased expression of Ly6C, a GPI-anchored glycoprotein expressed by hematopoietic derived c ells41,42.
Typically, Ly6C is used to distinguish subsets of murine myeloid populations. In peripheral CD4+ and CD8+
T-cells, Ly6C expression is indicative of engagement with cognate antigen and enhanced proliferation and effector function43–47. Ly6C is associated with T-cell activation in the context of intracellular pathogens, most often
viruses, and adoption of a Th1 phenotype by CD4+ T-cells43,44,48. CD4+ Ly6C+ T-cells are reported to produce
elevated levels of cytokines, including IL-27 and IFNγ. In CD8+ T-cells, Ly6C+ cells may identify a subset of
memory cells and its expression may facilitate homing to lymphoid t issues49,50. While Ly6C lacks a sequencebased homologue in human immune cells, studies of human and murine monocytes suggest that CD14 may be
a functional h
 omologue51, although expression of CD14 by T lymphocytes remains an open question.
Somewhat surprisingly, neither CD25 nor CD69, two additional markers of T-cell activation, were identified
by our analysis as features of T-cell populations that distinguish the treatment groups. This raises the question
regarding the role of Ly6C in the context of Cb infection and the mechanism(s) by which it impacts T-cell function, as well as for other markers of T-cell functional status in the context of Cb infection (e.g. KLRG1, CXCR3).
One of the most notable features of the overall response was the expression pattern of T-bet, a transcription
factor canonically associated with Th1 type immune responses. Computational analysis revealed that distinct
populations of T-bet+ CD4, CD8, and innate cells distinguish challenge responses in vaccinated and naïve mice,
suggesting a multi-faceted role for T-bet in response to Cb. Indeed, a report published as this manuscript was in
preparation demonstrated that T-bet deficient mice exhibited significant differences from CD4-deficient mice
in a vaccine and challenge study, indicating a role for T-bet beyond Th-1 r esponses29. T-bet influences both
innate and adaptive immunity by governing the maintenance of maturation in NK cells, enhancing T-cell function and IFNγ production in response to viruses and protozoa, and aiding in B-cell activation to promote viral
clearance52–55. Expression of T-bet in CD8+ T-cells induces IFNγ production, which can in turn lead to increased
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◂Figure 4.  Correlation of clusters to measures of vaccination and infection. For matched clusters from

tgHLA-DR3 mice, the correlation to measures of vaccination (antibody titer) and infection (spleen bacterial
burden, spleen %BW, and histology scores) was determined (Supp Fig. 5). Correlation matrix data were used
to generate a t-SNE map. T cell, B cell, and innate clusters are denoted by distinct shapes. (A) The hierarchical
structure of the correlation matrix was used to identify 7 modules (Suppl Fig. 5), and each module was colorcoded to indicate its position on the t-SNE. The outlined areas indicate the modules with the highest median
correlation coefficient for clinical measures within the matrix (Module 1 lower left, Modules 4 and 5 upper
right). (B–I) For each cluster, symbol size indicates correlation p-value while color is function of the correlation
coefficient to the antibody titer on Day 10 and 35 post-vaccination (B,C), or measures of infection (D–I). (J)
Individual panels show the median correlation coefficient for each clinical measure for each module. In the
lower right graph, modules are ranked based on the sum of the median correlation coefficients.

T-bet expression in B-cells and promote antibody class s witching53,55,56. Indeed, we observed T-bet expression
not only in T-cells, but also B-cell and innate populations, including NK cells. Post-challenge, increased expression of T-bet in B-cells, which likely promotes class switching to IgG2a, was detected in vaccinated tgHLA-DR3
mice57. This pattern of change is generally consistent with a Th1 response to an intracellular pathogen. The broad
role we describe here for T-bet in the in vivo response against Cb is in contrast to previous reports indicating
that TBX21, the gene for T-bet, is downregulated by Cb during in vitro granuloma f ormation58. These divergent
observations likely result from differences in human PBMCs stimulated and cultured in vitro58, as compared to
circulating immune cells obtained from mice following vaccination and challenge.
CD8 and NK cell populations expressing CD73 were enriched in vaccinated mice following both vaccination
and challenge. CD73 and CD39 are ectonucleotidases that convert extracellular ATP to adenosine, a suppressor
of inflammatory f unction59–63. In T-cells, CD39 and CD73 promote adhesion and co-stimulation while curtailing
effector function, and naïve CD8+ T-cells downregulate CD73 expression following a ctivation64,65. In the context
of Cb, we observed expression of CD73 on naïve CD8 T-cells in vaccinated mice on Day 10. However, on both
Day 10 and Day 35 post-vaccination, CD73+ CD44+ CD62L+ CD8 T-cells (central memory) are enriched in
vaccinated mice, which may reflect previously naïve CD8 cells that are in transition towards memory and helping
to suppress inflammation following vaccination.
There are additional considerations for interpretation of data generated in this study. The small blood volumes
available in a longitudinal study and BSL3 containment prevented inclusion of ex vivo stimulation and allowed
only for an abbreviated incubation with a Golgi secretion inhibitor. This likely limited the detection of cytokines,
including IFNγ, an established integral facet of the response to Cb18,26,66. The tgHLA-DR3 mice in this study
are on the BL/6 background, which exhibit less severe infection and mortality than some other s trains67. In this
regard, BL/6 background mice may more closely approximate the acute non-lethal disease observed in humans.
This study identified multi-faceted roles for multiple population markers and delineated minimal sets of cell
clusters to distinguish treatment groups as well as vaccinated mice that controlled Cb efficiently versus those that
did not. In particular, the observed importance of T-bet provides evidence supporting a Th1-biased immune
response to Cb. Similarly, the capacity of T-cell subsets to delineate naïve and vaccinated mice after 10 days
suggests a robust early T-cell response to vaccination. The profile of the immune alterations following Coxevac
vaccination and subsequent challenge detail the response to an effective, albeit potentially problematic, vaccine.
Future candidate vaccines that aim to provide effective protection while minimizing reactogenicity will likely
need to recapitulate canonical features of effective vaccination (IFNγ and antibody production) along with facets of the alterations in immune cell populations including participation of monocytes, depletion of circulating
mature NK cells, and the involvement of both naïve and memory T-cell populations.

Materials and methods

Mice. Female wild-type BL/6 mice, NCI A/JCr (AJ) and Balb/c mice (6–8 weeks old) to assess inactivation of
Cb were obtained from Jackson Labs (Bar Harbor, ME, US). Female mice transgenic for HLA-DR3 (5–11 weeks
old) were obtained under commercial license68. Mice were maintained under BSL3 conditions in microisolator
cages (Smart Flow, Tecniplast, Westchester, PA, USA) at the Regional Biocontainment Laboratory, Colorado
State University, Fort Collins, CO, USA. Animals were provided water and rodent chow ad libitum and evaluated
daily to detect changes in body weight, body condition, behavior, and activity level. All studies were performed
in accordance with all institutional guidelines and regulations under a protocol approved by the Colorado State
University Institutional Animal Care Committee (16–6,844) and following approval by the Animal Care and Use
Review Office (ACURO).
Coxiella strains. A stock of Coxiella burnetii (Cb) Nine Mile strain was prepared using axenic culture con-

ditions. Propagation was as d
 escribed69 using acidified citrate cysteine medium (ACCM-2) pH 4.75 (Sunrise
Science Products, San Diego, CA, USA) seeding flasks with 106 genome equivalents (GE) of Cb Nine Mile strain
phase 1 RSA 411 (BEI Resources, Manassas, VA, USA). Flasks were incubated for nine days on a shaker (75 rpm)
at 37 °C in 2.5% O2, 5% CO2 environment. Bacteria were recovered by centrifugation (18,000×g, 30 min), resuspended in sucrose phosphate buffer, and stored at – 80 °C70. The GE/mL of the stock was determined to be
2.17 × 107 GE/µL by quantitative polymerase chain (qPCR) using the LSI VetMax Cb absolute quantification kit
(Life Technologies, Lissieu, France) and Light Cycler 480 (Roche Diagnostics, Indianapolis, IN, USA.). Infectivity was initially confirmed by i.p. injection into NCI A/JCr mice and was further assessment by i.p. injection
into (4 × 104 and 4 × 105 genome equivalents) BALB/c mice. For both A/JCr and BALB/c mice, infection was
measured on Day 10 post infection and confirmed by presence of splenomegaly and quantification of bacterial
burden by qPCR.
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Figure 5.  Matched Clusters Predictive of Experimental Treatment Group. For each timepoint, EN analysis identified
matched clusters predictive of experimental groups. Clusters that distinguished (A,B) vaccinated from naïve mice, and (C,D)
vaccinated challenged from naïve challenged mice, are plotted according to the magnitude of their logit coefficient, a measure
of the influence of change in the abundance of the cluster between experimental groups on the predictive value of the cluster.
The position of individual clusters identified by EN are indicated on the adjacent t-SNE map, coloring and outlined areas
indicate modules defined in Fig. 4 (Module 1 lower left, Modules 4 and 5 upper right).
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Minimal cluster set distinguishing vaccinated and naïve mice following vaccination and challenge

Predictors

D10

D35

D44

D51

T D10 Cluster 6

B D35 Cluster 10

T D44 Cluster 19

I D51 Cluster 5

B D10 Cluster 15

I D35 Cluster 6

T D44 Cluster 13

T D51 Cluster 23

T D10 Cluster 1

I D35 Cluster 9

I D44 Cluster 8

I D10 Cluster 11

I D35 Cluster 11

I D44 Cluster 6

I D10 Cluster 10

I D35 Cluster 19

I D10 Cluster 5
Accuracy

0.991267354

0.978123601

0.950747569

0.867281627

95% CI (Accuracy)

0.989597557–0.991618568

0.976273511–0.979696496

0.946311676–0.954665136

0.857867203–0.876290465

F1 Score

0.990884218

0.978223994

0.942810354

0.853730454

Sensitivity

0.990993093

0.989126377

0.927925458

0.838666939

Specificity

0.991520317

0.967975207

0.970250839

0.891832809

Table 2.  Cluster sets to distinguish vaccinated and naïve mice after vaccination and challenge. The table lists
the minimal set of clusters that best distinguishes naïve and vaccinated mice on Day 10 and Day 35 or naïve
challenged mice from vaccinated challenged mice on Day 44 and Day 51, determined using unsupervised
computational analysis. The accuracy, 95% confidence interval (CI), F1 score, sensitivity, and specificity scores
are listed for each time point. Further details are provided in Supplementary Table 3.

Determination of the protective dose of Coxevac. A single lot (0101EG1A) of Coxevac (360 mL) was

provided by Ceva Animal Health (Lenexa, KS), and received by CSU under a USDA import permit. Coxevac
is a formalin inactivated phase I Cb corpuscular antigen formulation preserved with thimerosal. Coxevac commercial concentration is in arbitrary “Q fever” antigenic units relative to a proprietary standard. A BCA protein
assay (Pierce Biotechnology, Rockford, IL, USA) determined a protein concentration of 86 µg/mL, and qPCR
measured 1.3 × 106 GE/mL. To determine the protective dose of Coxevac, BL/6 mice (n = 5 per dose, 14 weeks
old) were inoculated subcutaneously (s.c.) with saline containing serially diluted Coxevac (0, 0.4, 2, and 10 µg).
At Day 42 post-vaccination, mice were challenged i.n. with 1 × 105 GE of Cb. Mice were sacrificed on Day 52
(10 days post-challenge), and heart, liver, lung, and spleen were harvested. Histological lesions were scored on
a graded scale of 0–4 (0 = no lesions; 1 = minimal, < 5% affected; 2 = mild, 5–10% affected; 3 = moderate, 10–25%
affected; 4 = severe, > 25% affected). The splenic bacterial burden was determined by qPCR and spleen/body
weight ratios were calculated.

Vaccination with Coxevac and subsequent challenge with live Cb. Two sets of 16 tgHLA-DR3

mice (5–11 weeks old) were randomly assigned to two and four groups respectively. Mice were vaccinated s.c.
with 10 µg (100 µL) of Coxevac at Day 0; mice in control groups received phosphate buffered saline (PBS) (100
µL). At Day 42, mice were chemically restrained (ketamine, 100 mg/kg and xylazine, 10 mg/kg, intraperitoneal
(i.p.) for inoculation with Cb by i.n. route with a target dose of 1 05 genome equivalents, as determined by qPCR,
in 20 µL. The control group (n = 5) received PBS (20 µL). Whole blood samples were collected from the submandibular region on Days 10, 24, 35, 44 and 51 and the resulting serum was used for serological analysis. The
white blood cells from 10, 35, 44, and 51 cells were analyzed by CyTOF. All mice were euthanized at Day 52 and
spleens were collected and weighed. Tissues (heart, lung, liver, spleen) were collected in 10% formalin for paraffin embedding and stained with hematoxylin and eosin for histopathological review. Histological lesions were
scored on a graded scale of 0–4 (0 = no lesions; 1 = minimal, < 5% affected; 2 = mild, 5–10% affected; 3 = moderate, 10–25% affected; 4 = severe, > 25% affected).

Inactivation of Cb in infected samples. To allow for analysis outside the BSL3 facility, a sample inactivation procedure was established to ensure that fixed blood samples from infected mice were safe for transport and
for subsequent immune marker assessment by CyTOF. Fixation in 4% paraformaldehyde for 1 h was determined
sufficient to eliminate infectivity in spleen cell suspensions used to inoculate A/J mice, which are highly permissive for Cb infection67. For each timepoint, barcoded and labeled leukocyte samples from infected mice were
incubated in 4% formaldehyde PBS solution for two hours to inactivate any infectious Cb and stored frozen. Due
to limited blood volumes, to confirm Cb inactivation for each timepoint, a representative splenic sample from an
infected mouse that had been previously aliquoted and stored following disassociation by serial passage through
70 mm and 40 mm filters was inactivated in parallel with the blood and stored in the same manner. The parallel inactivation at each timepoint of the banked Cb infected spleen sample provided a common control across
experiments to confirm Cb inactivation and enable blood sample release from the BSL3 facility. To confirm
inactivation, the representative splenic sample was injected i.p. into naïve susceptible NCI A/JCr mice and on
Day 10 post-inoculation with inactivated materials the spleens were recovered from the A/JCr mice. Inactivation
was confirmed by assessing splenomegaly and bacterial burden as detected by qPCR.
Murine blood collection. A solution of 169 mM EDTA, prepared from 500 mM EDTA (Thermo Fisher)
diluted in Milli-Q water, was used to pre-coat 200 μL capillary tubes. At each timepoint, 150–200 μL of whole
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◂Figure 6.  Identification of features characterizing vaccine efficacy following challenge. Linear discriminant

analysis (LDA) models were constructed for each timepoint to rank combinations of up to 3 clusters based on
the ability to distinguish naïve challenged mice (N = 7) from Cb-neg vaccinated challenged mice (N = 5) and
subsequently assess the distribution of Cb-pos mice (N = 3). The discriminant functions with high predictive
accuracy were used to project the three groups onto corresponding feature space and identify combinations
of cell populations where the Cb-pos mice trend towards the naïve vaccinated mice. LDA plots depict the
distribution of each group, where the center of the x-axis denotes the point where the naïve challenged and
Cb-neg vaccinated challenged groups are maximally separated and the y-axis reflects the count (or density
estimate). Adjacent to each LDA plot is a scatter plot for the respective constituents. The title of each plot
indicates the cluster identity and the frequency parent on the y-axis.

blood was collected per mouse by submandibular bleed into the capillary tubes. Blood samples from each mouse
were transferred to a 1.7 mL conical tube containing 22 μL of RMPI and 0.5 mg/mL brefeldin A and incubated at
room temperature for 45 min prior to red blood cell (RBC) lysis and antibody labelling of leukocytes.

Serology. Plasma was processed for serology as described p reviously71. Whole blood was collected as
described above. A 10 μL aliquot of plasma was recovered after centrifugation (300 g for 3 min) and stored at
-80C. Anti-Cb antibody levels in the plasma were determined by ELISA (Q Fever Ab Test, IDEXX Laboratories,
Westbrook, ME, USA). The secondary antibody was replaced with peroxidase conjugated protein A/G (Pierce
Biotechnology, Rockford, IL, USA) or goat anti-mouse IgG (H + L) (Jackson ImmunoResearch Laboratories,
Rockford, IL, USA). ELISA measurements were reported as absorbance values measured at 450 nm (OD450) and
baseline corrected, using plasma from naïve animals.
Mass cytometry. Whole blood collected at each timepoint was depleted of erythrocytes using the eBioscience 10X multispecies RBC lysis buffer. Following lysis, samples were barcoded, surface labelled with antibody,
and fixed prior to storage at − 80 °C until release following Cb inactivation confirmation. Subsequently samples
were thawed, labelled intracellularly, and analyzed by mass cytometry (see Supplementary Material).
Data analysis. Following acquisition of mass cytometry data, the resulting files were processed in accord-

ance with previously reported m
 ethods72–74. For each sample, data were normalized using bead standards to
account for machine variance, using proprietary software from Fluidigm. Viable single cells, T-cells, B-cells,
and innate cells were identified by manual gating with FlowJo 10 software (Supplementary Fig. 3a). Values from
mass cytometer channels containing non-biological data were removed and the resulting FCS files used for
downstream analysis. Statistical tests were performed as indicated in the figure legends using GraphPad Prism
V8, unless otherwise noted. Additional details provided in supplementary methods.

Clustering analysis and cluster matching. First, the data from each replicate experiment were considered independently. For each timepoint the data were manually divided into T-cell, B-cell, and innate cell populations (Supplementary Fig. 3). Then resulting populations from each timepoint were clustered independently
to identify the distinct subpopulations of cells present. Cell clusters were defined based on the abundance of the
markers detected on each cell, grouping together cells with highly similar profiles using the Vortex implementation of the X-shift algorithm, a k-nearest neighbors m
 ethod32, according to the labels as indicated in Fig. 2 and
in Supplementary Information. Cluster analysis used between 3.4e5 and 1.2e6 cells per timepoint from each
experiment. Subsequently, the differential abundance of each cluster between treatment groups was determined
for individual timepoints by pairwise t tests and visualized using S PADEVizR39 (Supplementary Fig. 6).
To identify phenotypically similar clusters conserved between two cognate replicate timepoints, cluster profiles from the replicate experiments were compared using Pearson’s correlation. The list of putative pairings was
ranked according to correlation value. Clusters with a frequency of less than 0.02% of input cells were removed
from the analysis and a lower limit of r = 0.6 was used to limit the number of candidate pairings. For each cluster, starting with the highest correlation value, candidate pairings were manually evaluated with the basis of
phenotype (cluster profile), overall distribution between treatment groups, and cluster size. In some instances,
candidate pairings with good phenotypic correlation and similar abundance did not have similar distributions
between experimental groups; however, this did not preclude acceptance as a matched pair. As a result of this
analytical approach, clusters with no corresponding match in the replicate experiment or with a frequency of
less than 0.02% of total input were excluded from further analysis.
Heatmaps, logistic regressions, correlation matrix, discriminant analysis, and t‑SNE.

Details
related to the production of heatmaps, Elastic Net logistic regression, correlation matrix calculation, t-SNE map
generation, and linear discriminant analysis are provided in Supplementary Material. Briefly, heatmaps and the
correlation matrix were both created used the R packages Pheatmap, using the Ward.D2 method for hierarchical
clustering, Pvclust for bootstrap analysis, and rcorr function for Spearmann correlation a nalysis75,76. NbClust
was used to determine the appropriate segmentation p
 arameters77. Elastic Net analysis of phenotypic classes and
individual clusters, as well as multi-mode classification to identify the minimal set of highly predictive clusters
and linear discriminant comparison of challenged mice, was performed using the R package caret78. Detailed
methods provided in Supplementary Material.
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Figure 7.  Manual assessment of expression of key markers following Cb vaccination and challenge. Manually gated populations were
used to determine the frequency of parent for Ly6C, T-bet+, or CD73+ cells in major immune populations from tgHLA-DR3 mice.
Heatmaps illustrate the median frequency of parent within each group of mice (n = 8) on Days 10 and 35 post-vaccination, and Days 2
and 10 post-challenge (study Days 44 and 51). The color-coded scale reflects the frequency of parent for each heatmap. The Kruskal–
Wallis test for non-parametric data was used to identify statistically significant changes based on pairwise comparisons between
treatment groups within each timepoint; the p-value for significant changes are indicated on the graph.
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Figure 8.  Manual assessment of expression of key markers following Cb vaccination and challenge. Manually
gated populations were used to determine the frequency of parent for Ly6C+, T-bet+, or CD73+ cells in major
immune populations from tgHLA-DR3 mice. Heatmaps illustrate the median frequency of parent within each
group of mice (n = 8) on Days 10 and 35 post-vaccination, and Days 2 and 10 post- challenge (study Days 44 and
51). The color-coded scale reflects the frequency of parent for each heatmap. The Kruskal–Wallis test for nonparametric data was used to identify statistically significant changes based on pairwise comparisons between
treatment groups within each timepoint; the p-value for significant changes are indicated on the graph.
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Circos plot. The details of how the Circos plot was constructed is detailed in the Supplementary data
section35. The Circos plot was constructed with the R package Circlize79 and was structured to include 31 sections, representing each mouse included throughout the duration of the study: 8 sections each for Coxevac
unchallenged, Coxevac challenged and Naive unchallenged, and 7 sections for Naive challenged. For each timepoint, data from the two clusters with the highest positive or negative correlation coefficient to vaccinated or
vaccinated challenged mice were used. The heatmap mode was utilized to represent the correlation coefficient
with the value for each cluster rescaled to 0–1. Similarly, antibody titer, histopathology score, spleen %bw, and
bacterial burden were integrated into the Circos plot. Scatterplot mode was used to show the value of antibody
and body weight, while the histogram mode was used to indicate the pathology. A gradient color scheme was
applied to reflect the value of bacteria burden.

Data availability

Raw data, processed data, and source code for reproduction of the results are publicly available via https://flowr
epository.org/id/FR-FCM-Z2LH and https://github.com/reeves-lab.
Received: 10 December 2019; Accepted: 5 June 2020
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